Skip to main content

Table 1 Comparison of NADRI with ADRI in clinical and laboratory characteristics

From: Update on pathogenesis and diagnosis flow of normoalbuminuric diabetes with renal insufficiency

Item

Rigalleau 2007[18]

Afghahi 2013[37]

Shimizu 2013 [56]

De cosmo 2014[36]

Thorn 2015[47]

Penno 2018[7]

Lamacchia

2018[15]

Yamanouchi

2019[13]

Buyadaa

2020[16]

Dai

2021 [55]

N

15/74

10,111/6211

15/139

13,660/14,684

78/424

1476/1230

719/676

82/164

432/345

45/95

Age (years)

68 ± 9/64 ± 12

2.16 ± 2.10/1.99 ± 1.23

62.5 ± 6.2/62.1 ± 9.6

74.0 ± 8.0/73.4 ± 8.5

55.1(45.5, 61.3)/43.7(36.1, 50.7) *

74.4 ± 8.1/73.2 ± 9.1

66 ± 12/60 ± 14*

63(56, 67)/64(56, 70)

66.7(62.4, 72)/66.0(62.1, 71.2) *

67.6 ± 12.2/66.2 ± 12.1

Female (%)

66/40

64/42*

53.3/34.5

57.8/40.5*

77/42*

60.23/37.72*

65/41.5*

34/32

58.4/50.2*

48.9/42.1

BMI (kg/m2)

27.0 ± 4.5/26.9 ± 4.3

29.3 ± 5.2/29.5 ± 5.3*

22.2 ± 2.2/23.5 ± 3.4

29.7 ± 5.1/30.0 ± 5.2

25.2 ± 3.3/25.9 ± 4.1

29.06 ± 5.12/29.14 ± 5.05

26.2 ± 4.5/26.5 ± 4.9

23(21, 25)/24(22, 26)

32.4 ± 5.4/32.7 ± 5.7

25.4(23.2, 26.8)/24.2(22.3, 25.7)

Smoking (%)

20/52

6.1/8.0*

–

8.8/13.4*

12.0/24.0*

36.65/46.75*

13.5/24.3*

63/61

6/12.7*

20/29.5

HTN (%)

–

–

–

–

–

92.89/95.04

53.9/61.9

-

-

75.6/88.4

SBP (mmHg)

143 ± 16/147 ± 19

136 ± 17/139 ± 19*

129.3 ± 14.3/146.9 ± 21.0*

139.5 ± 18.9/143.8 ± 20.5*

137 ± 20/147 ± 21*

138.6 ± 18.7/140.9 ± 19.6*

137 ± 20/141 ± 20*

130(120, 145)/146(134, 162)*

133.0 ± 17.0/144.8 ± 18.8*

137 ± 20/152 ± 22*

DBP(mmHg)

79 ± 8/81 ± 10

73 ± 9.8/74 ± 10.3

75.6 ± 10.0/76.8 ± 12.4

77.3 ± 9.8/78.5 ± 10.3

75 ± 9/82 ± 11*

77.4 ± 9.7/77.6 ± 10.1

76 ± 10/78 ± 10*

75(68, 80)/80(70, 90)*

70.8 ± 10.6/72.6 ± 12.0*

79 ± 12/85 ± 12*

HbA1c (%)

9.0 ± 1.3/8.5 ± 1.6

6.97 ± 3.16/7.25 ± 3.38*

8.3 ± 2.2/7.4 ± 2.0

7.4 ± 1.4/7.7 ± 1.5*

8.1 ± 1.2/9.0 ± 1.5*

7.58 ± 1.45/7.85 ± 1.65*

8.0 ± 1.5/8.3 ± 1.7*

7.2(6.5, 9.0)/6.9(6.0, 8.3)

8.1 ± 1.0/8.3 ± 1.0

8.3 ± 2.5/9.0 ± 2.3

DD (years)

14 ± 5/19 ± 11

10.0 ± 7.7/13.0 ± 8.2

7.4 ± 6.4/13.1 ± 8.8*

13.3 ± 10.4/15.3 ± 10.5*

35.8(22.8, 45.7)/30.1(24.4, 35.6)

16.4 ± 11.3/18.3 ± 10.9

27 ± 15/27 ± 13

12(8, 18)/13(8, 21)

10(6, 16)/15(8, 21)

8(2, 15)/13(10, 20)*

TG (mmol/L)

2.16 ± 2.10/1.99 ± 1.23

1.9 ± 1.0/2.1 ± 1.2*

–

1.71 ± 0.99/1.88 ± 1.22*

0.99(0.81, 1.24)/1.47(1.08, 2.24)*

1.45(1.07, 2.05)/1.60(1.18, 2.25)

1.24 ± 0.84/1.54 ± 1.00*

1.5(1.1, 2.2)/1.7(1.2, 2.4)

1.93(1.34, 2.73)/2.12(1.41, 2.95)

1.34(1.03, 1.89)/1.74(1.23, 2.52)

TC (mmol/L)

6.12 ± 1.73/5.43 ± 1.24

4.8 ± 1.1/4.7 ± 1.1

5.08 ± 1.33/5.89 ± 2.60

4.80 ± 1.05/4.74 ± 1.10

4.91 ± 0.94/5.29 ± 1.22*

4.79 ± 1.02/4.78 ± 1.09

4.97 ± 0.98/5.12 ± 1.24*

5.0(3.9, 5.8)/5.4(4.6, 6.4)*

4.83 ± 1.07/4.81 ± 1.17

4.38(3.69, 5.44)/4.99(4.23, 5.97)*

HDL-C (mmol/L)

1.66 ± 0.72/1.34 ± 0.44*

1.3 ± 0.4/1.2 ± 0.4

–

1.28 ± 0.36/1.20 ± 0.35*

1.51 ± 0.45/1.19 ± 0.41*

1.27 ± 0.36/1.20 ± 0.36

1.58 ± 0.49/1.50 ± 0.52*

1.0(0.8, 1.3)/1.1(0.8, 1.5)

1.09 ± 0.29/1.03 ± 0.29

1.10(0.98, 1.34)/1.08(0.88, 1.31)

LDL-C (mmol/L)

3.26 ± 1.19/3.08 ± 1.03

2.7 ± 0.9/2.6 ± 0.9

–

2.75 ± 0.88/2.69 ± 0.89

2.91 ± 0.91/3.26 ± 0.99*

2.77 ± 0.86/2.73 ± 0.88

2.82 ± 0.83/2.95 ± 0.98*

2.8(2.1, 3.4/3.3(2.6, 4.1)*

–

2.74(1.98, 3.24)/2.80(2.30, 3.77)

DR (%)

26/66*

20/31*

50.0/87.9*

18.5/30.5

–

23.51/41.87*

7.8/13.3*

62/69

17.4/29.9

4.4/41.1*

DN (%)

–

–

–

–

–

–

–

–

–

44.4/71.6*

CVD (%)

13/38

31/39*

–

–

19/17

33.54/45.69*

–

–

39.8/48.1*

8.9/7.4

  1. Data are presented as percentages or medians (interquartile range) or mean ± SEM or mean ± SD. *means P < 0.05. NADRI normoalbuminuric diabetes with renal insufficiency, ADRI albuminuric diabetes with renal insufficiency, N number, BMI body mass index, HTN hypertension, SBP systolic blood pressure, DBP diastolic blood pressure, HbA1c glycated hemoglobin, DD diabetes duration, TG triglycerides, TC total cholesterol; HDL-C high-density lipoprotein cholesterol, LDL-C low-density lipoprotein cholesterol, DR diabetic retinopathy, DN diabetic neuropathy, CVD cardiovascular disease